International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A. Arber, Michael R. Savona, Elli Papaemmanuil et al.|Blood|2022Cited by 2.7k
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al.|Haematologica|2015Cited by 252
World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and managementWilliam Shomali, Jason Gotlib|American Journal of Hematology|2019Cited by 191
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and managementWilliam Shomali, Jason Gotlib|American Journal of Hematology|2021Cited by 172
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162